No Cover Image

Journal article 210 views

Repurposing metabolic drugs as anti-inflammatory agents

Andrew E. Hogan Orcid Logo, Cian Davis, Benjamin Jenkins, Nick Jones Orcid Logo, Donal O’Shea Orcid Logo

Trends in Endocrinology & Metabolism

Swansea University Authors: Benjamin Jenkins, Nick Jones Orcid Logo

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1016/j.tem.2025.07.003

Abstract

Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have ente...

Full description

Published in: Trends in Endocrinology & Metabolism
ISSN: 1043-2760 1879-3061
Published: Elsevier BV 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa70229
Abstract: Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents.
Item Description: Review
Keywords: obesity; glucagon-like peptide-1; SLGT2i; inflammation
College: Faculty of Medicine, Health and Life Sciences
Funders: A.E.H. and D.O.S. are supported by a Health Research Board Grant (ILP-POR-2024-019). N.J. is supported by an MRC New Investigator Research Grant (MR/X000095/1).

Similar Items